![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Production & Manufacturing
News
Oxgene introduces TESSA technology for plasmid-free manufacturing system for Adeno-associated virus
Oxgene, a biotechnology company designing and developing scalable gene therapy technologies, has announced the launch of its scalable, plasmid-free manufacturing system for Adeno-associated virus...
Press Releases
T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy
T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid tumors, and Catalent, the leading...
News
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply
Samsung Biologics and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing...
News
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
BioNTech SE announced the signing of a share purchase agreement with Novartis AG, Basel / Switzerland to acquire their GMP certified manufacturing facility in...
Press Releases
GigaGen Initiates Large-Scale Manufacturing of its First-in-Class Recombinant Hyperimmune Drug for COVID-19, GIGA-2050
GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced the company has initiated large-scale...
News
Catalent Invests $130 Million to Add Additional Manufacturing Capacity at its Gene Therapy Campus in Harmans, Maryland
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products,...
Drug Research
Memo Therapeutics and Northway Biotech collaborate on the fast-track manufacturing of a SARS-CoV-2-neutralizing antibody for the therapy of COVID-19
Swiss biotech company Memo Therapeutics AG (MTx), and Northway Biotechpharma (Northway), a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announce a new partnership...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read